De Novo Development of Distal Jejunal and Duodenal Adenomas After 41 Months of Teduglutide Treatment in a Patient With Short‐Bowel Syndrome: A Case Report. Issue 3 (21st August 2020)

• Record Type: Journal Article
• Authors: Pevny, Sophie; Pape, Ulrich‐Frank; Elezkurtaj, Sefer; Rieger, Anja; Jürgensen, Christian; Blüthner, Elisabeth; Jochum, Christoph; Tacke, Frank; Maasberg, Sebastian
• Is Part Of: JPEN, Journal of parenteral and enteral nutrition. Volume 45:Issue 3(2021)
• Page Start: 652
• Page End: 656
• Publication Date: 2020-08-21
• Subjects: duodenal adenoma -- endoscopy -- glucagon‐like peptide 2 -- intestinal failure -- jejunal adenoma -- parenteral nutrition -- short bowel syndrome -- teduglutide; Parenteral feeding -- Periodicals; Enteral feeding -- Periodicals; 615.85484
• DOI: 10.1002/jpen.1982
• Languages: English
• ISSNs: 0148-6071

Abstract

Abstract: The glucagon‐like peptide‐2 (GLP‐2) analogue teduglutide is a medical treatment option for patients with short‐bowel syndrome–associated chronic intestinal failure. Because studies in mice have shown that GLP‐2 analogues may promote the growth of colonic neoplasms, surveillance colonoscopies before and during teduglutide therapy were recommended. The occurrence of small‐intestinal neoplasms has not been reported so far, except for a recent report about de novo development of hamartomatous duodenal polyps. We report a case of de novo development of small‐intestinal premalignant adenomatous polyps in both bulbar duodenum and distal jejunum in a patient treated with teduglutide for 41 months. Therefore, additional endoscopic surveillance of the upper gastrointestinal tract may be advised during teduglutide therapy for early detection and removal of potential small‐bowel adenomas.